Heartflow, Inc. (NASDAQ:HTFL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Heartflow, Inc. (NASDAQ:HTFL) have received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $37.6667.

A number of research firms recently issued reports on HTFL. JPMorgan Chase & Co. lowered their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Canaccord Genuity Group upped their price target on shares of Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wells Fargo & Company dropped their price objective on Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday.

Heartflow Stock Up 0.5%

Shares of HTFL stock opened at $26.02 on Friday. Heartflow has a 12 month low of $20.13 and a 12 month high of $41.22. The company has a market cap of $2.23 billion and a PE ratio of -14.38. The business’s 50 day moving average is $26.86 and its two-hundred day moving average is $30.41.

Insiders Place Their Bets

In related news, CEO John C.M. Farquhar sold 22,562 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $27.46, for a total transaction of $619,552.52. Following the transaction, the chief executive officer owned 591,656 shares of the company’s stock, valued at approximately $16,246,873.76. The trade was a 3.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Campbell Rogers sold 65,153 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $24.49, for a total transaction of $1,595,596.97. Following the transaction, the insider owned 76,034 shares of the company’s stock, valued at approximately $1,862,072.66. The trade was a 46.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 2,127,399 shares of company stock valued at $59,295,771.

Institutional Trading of Heartflow

Several institutional investors have recently modified their holdings of HTFL. Wellington Management Group LLP increased its position in shares of Heartflow by 20.8% during the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after purchasing an additional 1,014,006 shares during the period. Baillie Gifford & Co. acquired a new stake in Heartflow during the third quarter worth $101,182,000. Bamco Inc. NY increased its holdings in Heartflow by 86.2% in the 4th quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock valued at $67,158,000 after buying an additional 1,066,371 shares during the period. Schusterman Interests LLC acquired a new position in shares of Heartflow in the 3rd quarter valued at $65,274,000. Finally, Capricorn Investment Group LLC bought a new position in shares of Heartflow during the 4th quarter worth about $48,178,000.

More Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong top‑line growth — HeartFlow reported revenue of $49.13M vs consensus $46.58M, up ~40.5% year‑over‑year, signaling accelerating adoption and top-line momentum. MarketBeat: Q4 results & transcript
• Positive Sentiment: Bullish analyst move — Canaccord raised its price target to $43 and maintained a Buy rating, implying a sizable upside and providing supportive institutional sentiment. Benzinga: Canaccord price target raise
• Neutral Sentiment: Analysts cut targets but stayed positive — JPMorgan lowered its PT from $40 to $35 but kept an Overweight rating, signaling confidence in the business even while trimming valuation assumptions. Benzinga: JPMorgan PT change
• Neutral Sentiment: Wells Fargo also trimmed its PT (from $38 to $35) but maintained an Overweight rating, another sign of cautious optimism. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Independent analysis available — Seeking Alpha published a piece reviewing HeartFlow’s strategy and growth opportunities; useful for investors analyzing the longer‑term thesis. Seeking Alpha: HeartFlow: Getting Into The Flow
• Negative Sentiment: EPS miss and continued losses — HeartFlow reported GAAP EPS of ($0.29) vs consensus ($0.16), missing estimates and underscoring margin pressure and ongoing unprofitability (PE remains negative). MarketBeat: EPS miss / earnings details
• Negative Sentiment: Valuation and trend considerations — Despite the rally, the stock remains below its 50‑day and 200‑day moving averages and carries a wide range of analyst targets, indicating continued volatility and mixed near‑term sentiment. Benzinga: HTFL earnings & estimates

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.